Literature DB >> 893736

Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.

D Lavene, Y A Weiss, M E Safar, Y Loria, N Agorus, D Georges, P L Milliez.   

Abstract

The intravenous and oral pharmacokinetics and the hepatic extraction ratio of pindolol were determined in 24 hypertensive patients with normal or impaired renal function. In patients with normal renal function, the total clearance was the sum of equal parts of the renal and nonrenal clearances. The nonrenal clearance was found to be equal to the hepatic clearance directly measured from the hepatic extraction ratio. Compared to patients with normal renal function, patients with chronic renal failure exhibited (i) unchanged K12 and K21 and nonrenal clearances, and (ii) significantly decreased values in half-life of the beta phase, Kel, and total renal clearance. The renal clearance was positively correlated (P less than 0.01) to the creatinine clearance. Bioavailability was significantly reduced (P less than 0.01) in the patients with renal failure. Assuming that the nonrenal clearance was equal to the hepatic clearance, the study provides evidence that, in patients with renal insufficiency, (i) no increased metabolism accompanies the decrease in renal function, and (ii) decreased availability is due to reduced absorption.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 893736     DOI: 10.1002/j.1552-4604.1977.tb05643.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

Review 1.  Hepatic first-pass metabolism in liver disease.

Authors:  T F Blaschke; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

2.  Estimation of the absolute oral bioavailability of pindolol by two analytical methods.

Authors:  M Guerret; G Cheymol; J P Aubry; A Cheymol; D Lavene; J R Kiechel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Pharmacokinetics of pindolol in Africans.

Authors:  L A Salako; A Ragon; R A Adio; A O Falase
Journal:  Experientia       Date:  1979-02-15

6.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

7.  Elimination of nadolol by patients with renal impairment.

Authors:  J Herrera; R A Vukovich; D L Griffith
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

8.  beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.

Authors:  L A Salako; A O Falase; A Ragon; R A Adio
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

9.  Study of the bioavailability of pindolol in malabsorption syndromes.

Authors:  D Evard; J P Aubry; Y Le Quintrec; G Cheymol; A Cheymol
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Pharmacokinetics of mepindolol in patients with chronic renal failure.

Authors:  W Krause; D Kampf; H C Fischer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.